From Reactive to Proactive: The New MAH Compliance Standard

As global regulatory expectations evolve, one trend is unmistakably clear: Marketing Authorization Holders (MAHs) must take a more proactive role in monitoring and managing supplier compliance. Recent changes by the UK Medicines and Healthcare products Regulatory Agency (MHRA) highlight this shift, placing greater responsibility on industry to identify and respond to regulatory risks — not wait for notifications.

For MAHs operating across the EU and UK, this change reinforces a fundamental reality: regulatory actions issued in one market can have real consequences across the entire global supply chain.

Why This Matters for Marketing Authorization Holders

Historically, the MHRA notified companies when their suppliers were the subject of FDA Warning Letters. However, the agency's updated approach now places the onus squarely on MAHs to:

• Monitor FDA Warning Letters and other global regulatory actions
• Strengthen supplier qualification and oversight procedures
• Ensure their own risk assessment and escalation processes are robust, timely, and documented

This aligns with the expectations already established by the EMA and EU national competent authorities. MAHs are expected to know when their contract manufacturers or API suppliers face compliance issues — and take swift, appropriate action to protect product quality and patient safety.

The Increasing Complexity of Global Oversight

The interdependence of today's pharmaceutical supply chain means a warning issued overseas can quickly escalate into operational or regulatory disruption locally. EU and UK regulators share information with the FDA, evaluate foreign inspection findings, and take coordinated action when patient safety may be at risk.

For MAHs, this increasing complexity requires:

• Continuous monitoring of international regulatory updates
• Strong technical and quality agreements with third party suppliers
• Clear internal processes for assessing impact and determining next steps
• The ability to rapidly activate alternative suppliers when necessary

This shift represents not just a regulatory requirement, but a strategic imperative for maintaining continuity of supply and protecting market authorization.

How ProPharma Supports Marketing Authorization Holders

At ProPharma, we partner with MAHs globally to meet this higher standard of compliance through:

• Regulatory intelligence and monitoring of FDA, EMA, and MHRA actions
• Supplier qualification and oversight support, from auditing to risk management
• MAH readiness and compliance frameworks tailored to market expectations
• End to end lifecycle support, ensuring your product stays compliant from development through post marketing

We help organizations move from a reactive stance — responding only when issues arise — to a proactive compliance model that identifies risks early and protects authorization, supply, and patients.

The Bottom Line

Regulators are clear: proactive oversight is now an expectation, not an option.

With FDA Warning Letters and global inspection findings carrying cross‑border implications, MAHs must be vigilant, informed, and ready to act. Strengthened supplier oversight and robust internal processes aren't just good practice, they are essential to preventing an overseas warning from becoming a domestic compliance challenge.

ProPharma is here to support MAHs through this evolving landscape, ensuring you stay ahead of regulatory expectations with confidence.